Entrapment in plasma microparticles: A promising strategy for antigen delivery

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 102, Issue 6, 2014, Pages 1244-1254

  Fatima, Munazza T ^a   Ahmad, Ejaj ^a   Saleemuddin, Mohammed ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

adjuvant free immunization; cell mediated immune response; fibrin matrix; IgG2a IgG1 ratios; vaccine delivery

Indexed keywords

ANIMALS; ANTIBODIES; BIOCOMPATIBILITY; EMULSIFICATION; IMMUNE SYSTEM; IMMUNIZATION; PLASMAS; T-CELLS; VACCINES;

ADJUVANT-FREE; CELL-MEDIATED IMMUNE; FIBRIN MATRIX; IGG2A/IGG1 RATIOS; VACCINE DELIVERY;

ANTIGENS;

ANTIGEN; B7 ANTIGEN; BETA FRUCTOFURANOSIDASE; CALCIUM; CD86 ANTIGEN; GLUTARALDEHYDE; MINERAL OIL;

ANIMAL EXPERIMENT; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS LINKING; DRUG DELIVERY SYSTEM; FEMALE; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMA; PLASMA MICROPARTICLE; PROTEIN DEGRADATION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; IMMUNIZATION; IMMUNOLOGY; MEMBRANE MICROPARTICLE; PROCEDURES; RABBIT; TH1 CELL; TH2 CELL;

ANIMALS; ANTIGENS; CD8-POSITIVE T-LYMPHOCYTES; CELL-DERIVED MICROPARTICLES; DRUG DELIVERY SYSTEMS; IMMUNIZATION; MICE; MICE, INBRED BALB C; MINERAL OIL; PLASMA; RABBITS; TH1 CELLS; TH2 CELLS;

EID: 84903973678     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.33108     Document Type: Article

References (51)

1. Akag T, Baba M, Akashi M,. Biodegradable nanoparticles as vaccine adjuvants and delivery systems: Regulation of immune responses by nanoparticle-based vaccine. Adv Polym Sci 2012; 247: 31-64.
2. Oyewumi MO, Kumar A, Cui Z,. Nano-microparticles as immune adjuvants: Correlating particle sizes and the resultant immune responses. Expert Rev Vaccine 2010; 9: 1095-1107.
3. Jung T, Koneberg R, Hungerer KD, Kissel T,. Tetanus toxoid microspheres consisting of biodegradable poly(lactide-co-glycolide)- and ABA-triblock- copolymers: Immune response in mice. Int J Pharm 2002; 234: 75-90.
4. Cruz LJ, Tacken PJ, Fokkink R, Figdor CG,. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials 2011; 32: 6791-6803.
5. Rajapaksa TE, David DL,. Microencapsulation of vaccine antigens and adjuvants for mucosal targeting. Cur Immunol Rev 2010; 6: 29-37.
6. Pawar D, Goyal AK, Mangal S, Mishra N, Vaidya B, Tiwari S, Jain AK, Vyas SP,. Evaluation of mucoadhesive PLGA microparticles for nasal immunization. AAPS J 2010; 12: 130-137.
7. Zhao A, Rodgers VG,. Using TEM to couple transient protein distribution and release for PLGA microparticles for potential use as vaccine delivery vehicles. J Control Release 2006; 113: 15-22.
8. Okada, H,. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev 1997; 28: 43-70.
9. Pandey R, Khuller GK,. Nanotechnology based drug delivery system(s) for themanagement of tuberculosis. Indian J Exp Biol 2006; 44: 357-366.
10. Mao HQ, Roy K, Walsh SM, August JT, Leong KW,. DNA-chitosan nanospheres for gene delivery. Proceed. Intern Symp Control Rel Bioact Mater 1996; 23: 401-402.
11. Ahire VJ, Sawant KK, Doshi JB, Ravetkar SD,. Chitosan microparticles as oral delivery system for tetanus toxoid. Drug Dev Ind Pharm 2007; 33: 1112-1124.
12. Alpar HO, Somavarapu S, Atuah KN, Bramwell VW,. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev 2005; 57: 411-430.
13. Buzea C, Pacheco Blandino II, Robbie K,. Nanomaterials and nanoparticles: Sources and toxicity. Biointerphases 2007; 2: MR17-MR172.
14. Breen A, O'Brien T, Pandit A,. Fibrin as a delivery system for therapeutic drugs and biomolecules. Tissue Eng Part B Rev 2009; 15: 201-214.
15. Spicer PP, Mikos AG,. Fibrin glue as a drug delivery system. J Control Release 2010; 148: 49-55.
16. Ahmed TA, Dare EV, Hincke M,. Fibrin: A versatile scaffold for tissue engineering applications. Tissue Eng Part B Rev 2008; 14: 199-215.
17. Lorand L,. Cross links in blood: Transglutaminase and beyond. FASEB J 2007; 21: 1627-1632.
18. Greco F, de Palma L, Spagnolo N, Rossi A, Specchia N, Gigante A,. Fibrin-antibiotic mixtures: An in vitro study assessing the possibility of using a biologic carrier for local drug delivery. J Biomed Mater Res 1991; 25: 39-51.
19. Meyenburg S, Lilie H, Panzner S, Rudolph R,. Fibrin encapsulated liposomes as protein delivery system. Studies on the in vitro release behavior. J Control Release 2000; 69: 159-68.
20. Kumar TR, Vasantha Bhai M, Krishnan KL,. A freeze-dried fibrin disc as a biodegradable drug release matrix. Biologicals 2004; 32: 49-55.
21. Ho H.-O., Chen C.-Y., Diffusion characteristics of fibrin films. Int J Pharm 1993; 90: 95-104.
22. Calcaterra J, Van Cott KE, Butler SP, Gil GC, Germano M, van Veen HA, Nelson K, Forsberg EJ, Carlson MA, Velander WH,. Recombinant human fibrinogen that produces thick fibrin fibers with increased wound adhesion and clot density. Biomacromolecules 2013; 14: 169-178.
23. Gorodetsky R,. The use of fibrin based matrices and fibrin microbeads (FMB) for cell based tissue regeneration. Expert Opin Biol Ther 2008; 8: 1831-1846.
24. Rejinold NS, Muthunarayanan M, Deepa N, Chennazhi KP, Nair SV, Jayakumar R,. Development of novel fibrinogen nanoparticles by two-step co-acervation method. Int J Biol Macromol 2010; 47: 37-43.
25. Royce SM, Askari M, Marra KG,. Incorporation of polymer microspheres within fibrin scaffolds for the controlled delivery of FGF-1. J Biomater Sci Polym Ed 2004; 15: 1327-1336.
26. Osada T, Yamamura K, Yano K, Fujimoto K, Mizuno K, Sakurai T, Nabeshima T,. Distribution and serum concentration of sisomicin released from fibrin glue-sealed dacron graft in the rat and human. J Biomed Mater Res 2000; 52: 53-57.
27. Ahmad E, Fatima MT, Saleemuddin M, Owais M,. Plasma beads loaded with Candida albicans cytosolic proteins impart protection against the fungal infection in BALB/c mice. Vaccine 2012; 30: 6851-6858.
28. Ahmad E, Fatima MT, Owais M, Saleemuddin M,. Beaded plasma clot: A potent sustained-release, drug-delivery system. Ther Deliv 2011; 5: 573-583.
29. Jafri F, Saleemuddin M,. Immobilization of invertase on sepharose-linked enzyme glycosyl recognizing polyclonal antibodies. Biotechnol Bioeng 1997; 56: 605-609.
30. Praveen G, Sreerekha PR, Menon D, Nair SV, Chennazhi KP,. Fibrin nanoconstructs: A novel processing method and their use as controlled delivery agents. Nanotechnology 2012; 23: 095102.
31. Ho HO, Hsiao CC, Sokoloski TD, Chen CY, Sheu MT,. Fibrin-based drug delivery systems III: The evaluation of the release of macromolecules from microbeads. J Control Release 1995; 34: 65-70.
32. Laemmli UK,. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
33. Murray AM, Pearson IF, Fairbanks LD, Chalmers RA, Bain MD, Bax BE,. The mouse immune response to carrier erythrocyte entrapped antigens. Vaccine 2006; 24: 6129-6139.
34. Itokazu M, Yamamoto K, Yang WY, Aoki T, Kato N, Watanabe K,. The sustained release of antibiotic from freeze-dried fibrin-antibiotic compound and efficacies in a rat model of osteomyelitis. Infection 1997; 25: 359-363.
35. Sung HW, Chang WH, Ma CY, Lee MH,. Crosslinking of biological tissues using genepin and/or carbodiamide. J Biomed Mater Res 2003; 64: 427-438.
36. Sell SA, Francis MP, Garg K, McClure MJ, Simpson DG, Bowlin GL,. Cross-linking methods of electrospun fibrinogen scaffolds for tissue engineering applications. Biomed Mater 2008; 3: 1-11.
37. Moingeon P,. Strategies for designing vaccines eliciting Th1 responses in humans. J Biotechnol 2002; 98: 189-198.
38. Espuelas S, Irache JM, Gamazo C,. Synthetic particulate antigen delivery systems for vaccination. Immunologia 2005; 24: 208-223.
39. Gutierro I, Hernández RM, Igartua M, Gascõn AR, Pedraz JL,. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 2002; 21: 67-77.
40. Kanchan V, Panda AK,. Interactions of antigen-loaded polylactide particles with macrophages andtheir correlation with the immune response. Biomaterials 2007; 28: 5344-5357.
41. Katare YK, Muthukumaran T, Panda AK,. Influence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticles. Int J Pharm 2005; 301: 149-160.
42. Oyewumi MO, Kumar A, Cui Z,. Nano-microparticles as immune adjuvants: Correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 2010; 9: 1095-1107.
43. Mottram PL, Leong D, Crimeen-Irwin B, Gloster S, Xiang SD, Meanger J, Ghildyal R, Vardaxis N, Plebanski M,. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: Formulation of a model vaccine for respiratory syncytial virus. Mol Pharm 2006; 4: 73-84.
44. Sharp FA, Ruane D, Claass B, Creagh E, Harris J, Malyala P, Singh M, O'Hagan DT, Pétrilli V, Tschopp J, O'Neill LA, Lavelle EC,. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci USA 2009; 106: 870-875.
45. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann Martin F,. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008; 38: 1404-1413.
46. Horisawa E, Kubota K, Tuboi I, Sato K, Yamamoto H, Takeuchi H, Kawashima Y,. Size dependency of D, l -lactide/glycolide copolymer particulates for intra-articular delivery system on phagocytosis in rat synovium. Pharm Res 2002; 19: 132-139.
47. Owais M, Gupta CM,. Liposome-mediated cytosolic delivery of macromolecules and its possible use in vaccine development. Eur J Biochem 2000; 267: 3946-3956.
48. Agrewala JN, Owais M, Gupta CM, Mishra GC,. Antigen incorporation into liposomes results in the enhancement of IL-4 and IgG1 secretion: Evidence for preferential expansion of Th-2 cells. Cytokines Mol Ther 1996; 2: 59-65.
49. Delamarre L, Holcombe H, Mellman I,. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med 2003; 198: 111-122.
50. Audran R, Peter K, Dannull J, Men Y, Scandella E, Groettrup M, Gander B, Corradin G,. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine 2003; 21: 1250-1255.
51. Balasse E, Odot J, Gatouillat G, Andry M-C, Madoulet C,. Enhanced immune response induced by BSA loaded in hydroxyethylstarch microparticles. Int J Pharm 2008; 353: 131-138.